WO1999004244A1 - Systeme d'inspection comprenant le pretraitement des echantillons - Google Patents

Systeme d'inspection comprenant le pretraitement des echantillons Download PDF

Info

Publication number
WO1999004244A1
WO1999004244A1 PCT/US1998/014719 US9814719W WO9904244A1 WO 1999004244 A1 WO1999004244 A1 WO 1999004244A1 US 9814719 W US9814719 W US 9814719W WO 9904244 A1 WO9904244 A1 WO 9904244A1
Authority
WO
WIPO (PCT)
Prior art keywords
specimen
sample
cellular
atypia
machine
Prior art date
Application number
PCT/US1998/014719
Other languages
English (en)
Inventor
Norman J. Pressman
Richard A. Domanik
Original Assignee
Accumed International, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/895,756 external-priority patent/US6148096A/en
Priority claimed from US09/034,690 external-priority patent/US6430309B1/en
Application filed by Accumed International, Inc. filed Critical Accumed International, Inc.
Priority to EP98935713A priority Critical patent/EP0995103A1/fr
Priority to CA002297119A priority patent/CA2297119A1/fr
Priority to JP2000503407A priority patent/JP3916395B2/ja
Priority to AU84900/98A priority patent/AU8490098A/en
Publication of WO1999004244A1 publication Critical patent/WO1999004244A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1468—Optical investigation techniques, e.g. flow cytometry with spatial resolution of the texture or inner structure of the particle
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F1/00—Details not covered by groups G06F3/00 - G06F13/00 and G06F21/00
    • G06F1/16—Constructional details or arrangements
    • G06F1/20—Cooling means
    • G06F1/203—Cooling means for portable computers, e.g. for laptops

Definitions

  • the present invention relates to specimen or sample inspection systems and more particularly to systems in which human operators inspect a substantial number of individual specimens to locate a particular subset such as "suspicious," irregular or abnormal specimens.
  • specimen is not necessarily limited to a medical or biological specimen but may more generally extend to any sample item or portion of a group as a whole.
  • the present invention may thus find particular use in a variety of contexts such as, for example, examining histological specimens (i.e., tissue-section-based as in anatomic or surgical pathology), examining cytological specimens (i.e., cellular samples (such as those samples prepared from specimens taken from body cavity fluids, voided urine, sputum, and gynecological tract) as analyzed by cytotechnologists and cytopathologists, cytogeneticists, hematologists, neuroscientists, microbiologists, cell biologists, etc.), examining silicon wafers in an integrated electronic circuit manufacturing process in the semiconductor industry, and other materials inspection processes.
  • histological specimens i.e., tissue-section-based as in anatomic or surgical pathology
  • cytological specimens i.e., cellular samples (such as those samples prepared from specimens taken from body cavity fluids, voided urine, sputum, and gynecological tract) as analyzed by cytotechnologists
  • Pap smears which are routinely taken from women, facilitate the detection of pre-cancerous changes and/or the early stages of cancer, thus reducing the chances of any cancer or related abnormal condition spreading or advancing in clinical staging with the resultant negative impact on the prognosis for the patient.
  • a Pap smear is prepared by first collecting a vaginal, cervical and endocervical tissue sample from a patient. The sample is then fixed to a slide, for instance by alcohol fixation, and appropriately stained (in a manner similar to the Papanicolaon (Pap) procedure) to enable microscope-based visualization and analysis.
  • Figure 9 illustrates a conventional Pap smear.
  • the conventional Pap smear process is limited, because it produces large numbers of cells (50,000 to 300,000 cells per Pap smear, typically) that are often obscured by inflammatory and other materials that make accurate and sensitive diagnoses more difficult in some cases.
  • the Pap smear process is also limited because it deposits the cells in a spatially non-uniform manner that is difficult and time-consuming to analyze visually, as shown, for example, by Figure 9.
  • LBP liquid-based preparation
  • the Cytyc ThinPrep ® sample preparation generally comprises straining a sample through a filter having pores smaller than the average sample cell diameter but sufficiently large to allow passage of cellular fragments and other debris.
  • the LBP device pore diameter is about 40-50 micrometers.
  • the filter preferably has no rough edges or other features that would rupture the sample cells.
  • sample cells remain on the filter surface while the debris passes through, resulting in a filter surface enriched in sample cells and depleted in debris.
  • the filter surface is next pressed onto a microscope slide to transfer the sample cells from the filter surface to the slide.
  • the Cytyc ThinPrep ® sample preparation thus provides a more spatially uniform distribution of cells within the cellular disk (CD), as shown, for instance, by Figure 10.
  • the slide is then screened by a highly skilled technician ("cytotechnologist"), in an effort to determine the specimen adequacy and to identify possible cellular abnormalities in the specimen.
  • the cytotechnologist generates notes regarding each specimen deemed to have possible abnormalities.
  • the cytotechnologist then provides the specimen slide, together with these paper-based or electronic notes of his or her findings, to an expert cytopathologist (i.e., specialized physician) for further review and final specimen diagnosis.
  • the cytotechnologist To screen a Pap smear specimen, the cytotechnologist generally views the Pap smear slide containing the Pap smear through a conventional optical microscope to detect the presence of potentially rare cancer cells or cells exhibiting other abnormal conditions. Because a cancerous cell may appear in only one of thousands of locations in an otherwise normal-appearing specimen, however, the cytotechnologist must generally examine every area of the slide in order to make a valid (i.e., accurate) determination. Overlooking any area could potentially result in a false negative (FN) diagnosis. Further, many portions of the specimen slide may contain no cells at all, but the cytotechnologist must examine even those areas to at least determine the absence of pertinent (i.e., diagnostically significant) material.
  • FN false negative
  • the cytotechnologist determines that the specimen is unsatisfactory, satisfactory but limited, or satisfactory for analysis. If satisfactory, then the cytotechnologist determines either that the specimen contains suspicious material such as pre-cancerous or cancer cells, or that the specimen is apparently within normal limits. Typically, statistically speaking, "suspicious" and "abnormal" specimens may account for approximately 5% to 10% of Pap smears in the United States, in laboratories that are screening asymptomatic women. The remaining statistical 95% to 90% of the cases in turn are classified by the cytotechnologist as apparently normal.
  • a specimen contains even a single well-preserved and well-stained cancer cell out of tens or hundreds of thousands of cells, the cytotechnologist should find the specimen to be suspicious, or atypical or abnormal. Failure to identify a specimen properly as abnormal during this screening process may be disastrous, as it may leave a cancer undetected and untreated, and may ultimately lead to the death of the patient.
  • the cytotechnologist forwards all "suspicious,” or “atypical” or “abnormal,” specimens to a pathologist for detailed review and final diagnosis and "sign-out” in light of the cytotechnologist's notes and findings.
  • One of the pathologist's goals is to analyze the specimen at issue and determine based on medical expertise whether the specimen contains cancerous or pre-cancerous cells. In doing so, the pathologist must strive to minimize both false negative diagnoses and false positive diagnoses, as false negative diagnoses could leave cancer undetected, while false positive diagnoses could result in unnecessary or inappropriate, harmful and costly cancer treatment such as surgery, chemotherapy or the like.
  • the average number of Pap smear slides screened per day by cytotechnologists in the United States is on the order of only 50 to 60, corresponding to cytotechnologists typically spending less than 7 to 8 minutes reviewing each slide in order to carefully determine whether any abnormal cells are present.
  • cytotechnologists spend more time screening each slide they will theoretically make fewer false negative errors.
  • cytotechnologists spend more time screening each slide they will screen fewer slides each day, and the labor and cost of specimen screening will consequently rise. This is a difficult scenario for laboratories, in the United States for example, since the third-party health insurance reimbursement rates are typically so low that Pap tests are nominally or not profitable for many, if not most, clinical diagnostic cytology laboratories.
  • the present invention provides an integrated system that improves efficiency in specimen inspection and analysis.
  • the invention will be described herein is a clinical diagnostic cytology system.
  • the invention may be a process for inspecting multiple samples each prepared from cytological specimens, to facilitate classification of said specimens as either apparently within normal limits ("apparently-WNL") or apparently not within normal limits (“apparently-not- WNL").
  • the invention may, for instance, include the following functions:
  • Figure 1 is a block diagram illustrating the process flow in a preliminary embodiment of the present invention
  • Figure 2 is a flow diagram illustrating components employed and functions performed by a prescreening and screening system in the present invention
  • Figure 3 is an illustration of a automated microscope-based screening station that may be employed in the present invention
  • Figure 4 is a flow chart illustrating the process flow in a preferred embodiment of the present invention
  • Figure 5 is a functional block diagram of the process flow in a preferred embodiment of the present invention.
  • Figures 6a and 6b are illustrations of multiple information windows displayed in preview monitor in accordance with a preferred embodiment of the present invention.
  • FIG. 7 is an illustration of discrete cell images in an electronic monolayer preparation (EMP) as displayed in a preferred embodiment of the present invention
  • Figure 8 is an illustration of a microscope field-of-view containing cellular matter of interest within a preferred embodiment of the present invention
  • Figure 9 is a graphical representation of a conventional "Pap Smear" cervical cytology slide
  • Figure 10 is a graphical representation of a Cytyc ThinPrep ® cervical cytology slide
  • Figure 11 is an illustration of areas within a cellular disk (CD) that are occupied by cells or other light-absorbing objects, with circles overlaid on the CD to show the relative sizes, counts and positions of the typical fields-of- views; and
  • Figure 12 is a graphical representation showing coordinates and fields-of- view within a ThinPrep cellular disk that identify suspicious and abnormal cellular material.
  • Figure 1 illustrates a block diagram of the system flow in a preliminary embodiment of the present invention.
  • a specimen is collected and a sample such as a Pap smear or LBP is prepared from the specimen, for instance on a 1 x 3 inch slide with a 1 x 2 inch coverslipped area adjacent to a 1 x 1 inch typical slide label for patient and slide identification.
  • the sample is then subjected to a cytological screening system, which includes automated or interactive machine prescreening and visual screening by a cytotechnologist. Based on the screening process, the cytotechnologist determines either that the specimen is suspicious or that the specimen appears to be within normal limits.
  • FIG. 2 shows, by way of example, some of the functions that may be performed in the prescreening and screening stages 14, 16 of this invention. In combination, these stages are adapted for use in a clinical laboratory or similar facility, and preferably include an image capture apparatus 100, a mapper 104 and an automated microscope-based screening station 110.
  • the image capture apparatus 100 preferably takes the form of a camera and a frame grabber.
  • the camera is preferably a CCD (charge coupled device) scientific grade type camera with a IK x IK or larger format, and a 3 class or better sensor.
  • a CCD charge coupled device
  • Such a camera is available commercially under the trade name ES-1 from Kodak Corporation, Rochester, New York, and is also available from Pulnix America, Sunnyvale, California.
  • Such a camera is characterized by an active sensor area of 9mm x 9mm or larger with a pixel spacing of 9 microns or finer and can capture, or scan, images at a rate of at least 30 frames/second and provide a digital output at a minimum rate of 30 MHz.
  • the optical system is configured to provide an effective pixel resolution of approximately 2.4 microns at the sample.
  • the camera provides its digital output to a frame grabber, which operates to store the digital data received from the camera.
  • the frame grabber preferably employs a PCI type interface and is characterized by a data transfer rate of at least 50 MHz.
  • the frame grabber preferably also employs digital signal processing for optical shade correction and blob finding.
  • a preferred frame grabber takes the form of a Data Raptor type frame grabber available from Bit Flow Corp., Woburn, Massachusetts.
  • the frame grabber may perform certain image analysis and enhancement functions by way of specialized hardware devices, to provide a speed increase over performing such functions in software.
  • the frame grabber may be configured with specialized hardware, such as digital signal processing circuitry, to perform some of the functions described below as being performed by software.
  • Image capture of a sample on the slide 102 is preferably performed by subdividing the slide into a plurality of equally sized regions, illustrated by the dotted lines in the slide 102, and individually capturing digital images of the sample, region-by-region.
  • the digital image of each region is stored in a memory once captured and is analyzed by the mapper 104.
  • the regions of the slide shown in Figure 2 are simplified for sake of illustration. In practice, a slide will typically have far more regions than shown in Figure 2. For example, a typical slide that measures approximately 75mm x 25mm, with an area of roughly 50mm x 25mm being occupied by a sample. Such a slide will contain approximately 200 non-overlapping regions of approximately 2.5mm x 2.5mm.
  • the mapper 104 is implemented as a software program stored in a semiconductor, magnetic, optical or other similar type of storage device and executed by a general purpose digital computer.
  • a general purpose digital computer is the TRACCELL ® system available from AccuMed International, Inc., of Chicago, Illinois.
  • the mapper 104 performs automated image analysis of the captured digital images. For example, the mapper may operate to automatically analyze each region for the presence of cytological material. If any cytological material is detected, the region is designated by the mapper as a "screenable" region. In addition, the mapper may identify and exclude from subsequent analysis normal squamous and epithilial cells.
  • the TRACCELL ® system may be configured to make preliminary determinations about the sample as a whole, such as whether the sample is satisfactory (e.g., adequate) for analysis. Unsatisfactory samples may then be identified and returned without further analysis.
  • the basis for an "unsatisfactory" specimen may include unacceptable low cell counts and an under-stained or over-stained sample.
  • the mapper 104 generates a plurality of tiles as indicated at block 107. For simplified illustration, these tiles are shown as circles within the slide 102 at the screening station 110. Each of the tiles may correspond to a field-of-view selected for review by the cytotechnologist using the microscope at the screening station. Collectively, the tiles surround all of the cytological material determined by the mapper to be required for viewing by the cytotechnologist. For this reason, as those of ordinary skill in the art will appreciate, other tiling shapes and configurations, such as hexagons, may alternatively be employed to further improve screening efficiency.
  • the mapper 104 assigns spatial slide coordinates (including a focal plan coordinate) to each tile or sample region of interest and develops a routing function defining an optimal route for microscopic display of the designated areas of the sample. The mapper then transmits the coordinates to the screening station 110.
  • the screening station includes a microscope with a motorized stage and focus drive assembly, each of which may be operated by computer control or by an operator employing an ergonomic input device, or by a combination of computer and human control.
  • the screening station is coupled to the mapper 104 via a data communication link and, upon receiving a series of coordinates from the mapper, displays microscopic fields-of- view of the areas designated by the mapper in accordance with the routing function, or routing pattern, developed by the mapper.
  • a preferred screening station is the ACCELL ® specimen screening station produced by AccuMed International, Inc., of Chicago, Illinois.
  • Figure 3 illustrates an example of this station 110, which includes an automated electronic and optical imaging microscope (or video microscope) 210, to which a motorized stage 214, motorized focus driver (not shown) and motorized turret 220 have been fitted.
  • the automated microscope 210 may be an Olympus BX-40 microscope, available from Olympus Optical Corporation of Tokyo, Japan and preferably includes a set of lenses 216 individually selectable by a motorized control.
  • the screening station 110 includes a slide magazine 218, a slide holder 219, a bar code reader and printer 221, and a light source 222.
  • the motorized stage 214 moves along an axis designated as the Y-axis in Figure 3.
  • slide holder 219 is connected to the motorized stage 214 and is itself motorized to move along an axis designated as the X-axis in Figure 3.
  • a controller board within station 110 receives external control signals to control the operation and movement of the motorized stage and slide holder, thereby providing automated movement of the specimen slide 102 in two dimensions relative to the microscope lens 216.
  • the camera of the image capture apparatus 100 is affixed to a video port on the microscope 210, in order to capture cell images and avoid having to move the slide 102 between the microscope and the camera.
  • another embodiment excludes the intervening video port entirely and integrates the image capture apparatus with the microscope.
  • the mapper 104 is in turn coupled to the screening station by direct physical data links or by way of a data network such as a local area network. While neither the physical structure of the mapper, image capture apparatus and screening station nor the manner of coupling the mapper to the screening station is critical, such an arrangement allows the mapper to be physically separate from the screening station and allows the mapper to exchange information with a plurality of screening stations. Alternative arrangements of the manner in which the mapper and screening station are coupled, such as by way of example, a direct serial link, will be apparent to those of ordinary skill in the art in view of the present disclosure.
  • a cytotechnologist wishing to use the screening station 110 to view a slide inserts the slide or a group of slides into a slide carrier, which is then inserted into the slide magazine 218.
  • the system extracts a slide from the magazine and scans a bar code on the slide using the bar code reader 221.
  • the identity of the slide, as determined by the scanned bar code, is used by the system to retrieve coordinates from the mapper 104.
  • the slide is then transported from the magazine onto the stage and positioned in accordance with the coordinates received from the mapper 104.
  • the cytotechnologist may set the speed at which he or she reviews these fields-of- view presented at the screening station 110.
  • the cytotechnologist may, for instance, accelerate, decelerate or stop the automated review process.
  • the mode of automated review can also be changed at will by the user.
  • Such modes include, for example, step, stop-and- repeat screening, continuous screening, and slow-mode screening, among others.
  • the cytotechnologist may at any time elect to switch to a manual review mode, for instance, in order to review surrounding areas on the slide at issue without being limited to the established routing pattern.
  • the screening station 110 then enables the cytotechnologist to return to the automated routing pattern at the point that the cytotechnologist began to wander away from the established path. In this way, the station 110 helps to ensure that the cytotechnologist does not miss any areas of the specimen, including those that may be potentially critical to accurate diagnosis.
  • the screening system defined in part by the mapper 104 and the screening station 110 beneficially may be coupled to a database management system (DMS), for storage and display of information resulting from the screening process and other a priori information (such as patient demographics and medical history data) and in turn to facilitate passing pertinent findings to the expert pathologist for aid in diagnosis.
  • DMS database management system
  • the DMS preferably takes the form of a programmed general purpose desktop computer that has sufficient storage and processing capability to run, for example, a Microsoft Windows operating environment and an advanced database application such as Microsoft Access.
  • the cytotechnologist may, for instance, enter notes about an area of the sample, and those notes may be stored in the DMS together (in a database relationship) with the spatial coordinates of the area of interest, as provided by the mapper.
  • the reviewing pathologist may conveniently access the notes corresponding to a specified slide or area of a slide by, for instance, scanning a bar code or other identifying code associated with the slide, to access the corresponding information stored in the DMS.
  • the pathologist may refer to the cytotechnologist's notes, various a priori information such as patient demographics and medical history, and the corresponding sample region or regions of interest, which may be simultaneously or subsequently visualized and reviewed with the benefit of simultaneously reviewing the patient demographics and patient history data.
  • FIG. 4 illustrates in general a process flow according to this improved embodiment.
  • Figure 5 illustrates in greater detail a functional block diagram of the improved embodiment.
  • a cytological specimen is collected and a sample is prepared from the specimen.
  • the sample is optically scanned, to acquire a set of image data into a preprocessor machine.
  • the preprocessor analyzes the digital image(s) of the sample and identifies cellular objects in the sample, such as normal and atypical intact cells, well stained or poorly-stained cells or cellular components, well preserved or poorly preserved cells or cellular components, subcellular organelle such as nuclei and nucleoli, regions of cytoplasm, cellular fragments, cellular debris, adjoining or overlapping cells appearing in clusters or clumps, and multiple cells appearing together as a tissue fragment.
  • the preprocessor then eliminates areas of the slide that do not contain cellular matter, thereby identifying "screenable regions" of the slide as described above.
  • the preprocessor estimates for each cellular object a probability that the cellular object is atypical ("probability of cellular atypia” or, more generally, "probability of object atypia”).
  • the preprocessor estimates a probability that the sample as a whole, and therefore the underlying specimen, is atypical ("probability of specimen atypia"), based at least in part on the estimated probabilities of cellular atypia.
  • the preprocessor determines whether the estimated probability of specimen atypia falls within a range that would suggest the specimen is "suspicious" or "abnormal." These ranges may be determined by training the preprocessor to mimic the classification performance of expert cytopathologists on large number of training and test slides or other control data.
  • the ranges may correspond to diagnostic categories such as "within normal limits,” “pre-cancerous” and “cancer.” If the probability of specimen atypia falls within this range, then, at step 32, the preprocessor categorizes the specimen as “suspicious” or “abnormal.” In turn, at step 34, the preprocessor identifies the "suspicious” and “atypical” cellular objects in the specimen, based on their estimated probabilities of cellular atypia.
  • the preprocessor then presents those "suspicious” and "atypical” cellular objects to a cytotechnologist for screening at a screening station such as the TRACCELL ® - guided ACCELL ® workstation described above.
  • this screening process is aided by a "preview" system.
  • the preprocessor or other data management system compiles and presents to the cytotechnologist, prior to actual screening, a set of "biasing-information" (or a priori information) about the specimen.
  • the biasing- information which preferably includes discrete images of the most suspect cellular objects in the sample or the relocation of the cells in the microscope for human review prior to screening, is designed to enable the cytotechnologist to quickly form an educated opinion as to whether the specimen at issue is likely to be normal or is likely to be suspect. In turn, with knowledge of this a priori information, the cytotechnologist may efficiently spend more or less time actually screening the sample.
  • the preprocessor categorizes the specimen as "apparently- WNL.” Specimens categorized as apparently- WNL by the preprocessor are then either automatically classified as WNL, at step 40, or presented to a cytotechnologist for screening, at step 42.
  • the improved embodiment of the present invention takes the form of an integrated laboratory diagnostic system.
  • a cytological specimen is first collected from a patient, and a sample such as a Pap smear is prepared from the specimen.
  • the sample is then optically scanned and analyzed by the preprocessor.
  • the preprocessor may consist of one or more machines and preferably includes at least one computer processor and a set of software routines for carrying out the various functions described below.
  • the preprocessor is preferably interfaced with or connected to a file server, providing an electronic gateway to relevant information about specimens as will be described in greater detail below.
  • the preprocessing functions of the preferred embodiment may be entirely automated and carried out by the preprocessor machine(s).
  • the preprocessing functions may include both fully automated machine processing and human "processing" or interaction.
  • the machine and human processing may be independently performed or interactive in, for example, a closely coupled interactive operating environment with feedback from the machine to the human and from the human to the machine.
  • the preprocessing functions of the present invention may be carried out in either one pass or multiple passes.
  • the invention may involve first scanning a sample at low spatial and optical resolution and analyzing the low resolution image(s) to identify screenable regions and to eliminate artifacts.
  • the preprocessing image analysis may be conducted in black and white.
  • the invention may involve scanning the sample at a higher resolution, and possibly in full color, and analyzing the image(s) to categorize types of cellular matter in the sample (such as identifying "suspicious" or "abnormal" cellular objects or regions-of-interest.
  • the preprocessor serves in part as a specimen pre-screener.
  • This pre-screener preferably performs the functions of the TRACCELL ® system described above, such as detecting and mapping regions of the slide and eliminating unsatisfactory samples from further processing.
  • the preprocessor serves in part as a "suspicious and atypical event detector and analyzer" (also referred to as an "atypia analyzer").
  • the preprocessor identifies suspicious and abnormal cellular objects in the sample and, based on a statistical analysis of the level of atypia of these cellular objects, automatically categorizes the specimen as either (i) "apparently- WNL" or (iii) "suspicious or abnormal” (apparently-not- WNL).
  • the preprocessor preferably applies statistical and hierarchical pattern recognition techniques and thereby estimates for each cellular object a probability that the object is atypical (i.e., a "probability of cellular atypia"). More particularly, the preprocessor preferably analyzes the digitized images of sample regions or the discrete cellular objects already identified in the pre-screening stage, and compares features found in those images to certain morphological, photometric, spectral, and other features that, individually or collectively, have known meaning. These features may include, for example, specified size, shape, color, optical density range (gray level range or contrast), optical density distribution (texture), and topology (architecture relative to other cells) and combinations of such parameters.
  • the information (such as known features or "normal" ranges) referenced by the preprocessor in evaluating cellular atypia may be population-based and/or specimen-based.
  • Population-based information may be statistical information, such as averages, standard deviations and statistical moments of inertia, derived from large samples of patients. Such information may indicate generally that a given shaped cell is likely to have a given meaning.
  • Population-based information may also include information established from a control specimen known to be normal for a given population, and/or a control specimen known to be abnormal for the given population.
  • specimen- based information may be statistical information derived from the cells of the specimen at issue, thereby providing a personal or individualized baseline for the patient from whom the specimen was collected.
  • the preprocessor may also consider other factors related to the specimen at issue, in estimating probabilities of cellular atypia. These factors may include, for instance, data regarding patient medical history and demographics, such as an indication that the patient from whom the sample was drawn is particularly at risk for cancer or other diseases or has a history of abnormal Pap smears. Such information may automatically signal to the preprocessor that certain cellular objects that would otherwise be of little interest to a cytotechnologist may be more likely to be of interest. Conversely, such information may indicate that objects having generally atypical traits may in fact be normal for the particular patient.
  • the preprocessor may adjust its estimates of cellular atypia based on such a priori information.
  • the preprocessor assigns an estimated probability of cellular atypia to each cellular object of the sample. For instance, a probability of 1.0 may represent the most atypical object (such as a clearly cancerous cell), and a probability of 0.0 may represent the least atypical or the most normal object (such as a healthy cell).
  • the preprocessor then stores in a buffer the coordinates of cellular objects (or fields-of- view containing cellular objects) that have varying estimated probabilities of cellular atypicality.
  • the preprocessor preferably ranks these objects in descending order of probability of atypia, thus providing a ready indication of the most suspect objects of the sample.
  • the preprocessor may compute and store an indication of its level of confidence in each of its probability estimates, such as, for instance, an indication that it is 80% certain that an area is of interest (e.g., atypical or complex), or that it is only 20% confident in its finding. Based on its estimates of probabilities of cellular atypia for the cellular objects in the sample, the preprocessor then preferably derives a statistical atypia distribution for the sample as a whole. This statistical atypia distribution will serve as the basis for a quantitative an evaluation or estimate of the probability that the sample as a whole (and in turn the underlying specimen) is atypical (or "probability of specimen atypia").
  • the x- axis of the distribution may be the estimated probability of cellular atypia
  • the y-axis of the distribution may be the number of cellular objects in the sample having that estimated probability.
  • the preprocessor may additionally weigh, or adjust, this statistical distribution based on a knowledge of various factors that may affect the estimate, to the extent the preprocessor did not already consider those factors in estimating individual probabilities of cellular atypia. For instance, the preprocessor might adjust its estimated probability of specimen atypia based on information about patient medical history or demographics.
  • the preprocessor may decide whether or not the specimen is apparently- WNL. For instance, if all of the cellular objects in the sample have zero probability of cellular atypia, then the statistical atypia distribution for the sample will indicate a zero probability of specimen atypia. On the other hand, if the distribution resembles a Poisson distribution peaking at around 0.9 probability of atypia with the tail of the distribution going toward 0.0, then the preprocessor may well conclude that the specimen is abnormal or at least suspicious.
  • the preprocessor may conclude that the specimen is apparently-not- WNL and is likely to be suspicious or abnormal.
  • Path "A" in Figure 5 represents the specimens that the preprocessor categorized as apparently- WNL.
  • the preprocessor or other machine (or person) may then automatically classify and report some or all of these "apparently- WNL" specimens as WNL.
  • some or all of these "apparently- WNL" specimens may be presented to a cytotechnologist for quality control screening.
  • the cytotechnologist may conduct this quality control screening of "apparently- WNL" samples with an automated microscope workstation such as the ACCELL ® workstation described above.
  • the TRAcCELL ® -like portion of the preprocessor may control the movement of a motorized microscope stage at the workstation, by transmitting the coordinates of specimen regions to the workstation, thereby efficiently guiding the cytotechnologist through screenable regions of the specimen.
  • the cytotechnologist may more quickly screen the sample than would otherwise have been possible absent the preprocessor of the present invention.
  • the cytotechnologist determines that the specimen is either (i) suspicious or abnormal, as shown at block 58, or (ii) WNL, as shown at block 60. All apparently- WNL specimens that are deemed by the cytotechnologist to be suspicious or abnormal are then forwarded to an expert pathologist for review and final diagnosis. In contrast, those apparently- WNL specimens that are deemed by the cytotechnologist to be WNL are classified and reported as WNL. As shown by path "C" in Figure 5, however, at least 10% of the apparently- WNL samples that are deemed by the cytotechnologist to be WNL are preferably re-screened for added quality control.
  • all specimens that the preprocessor categorized as "suspicious” or “abnormal” are processed by the atypia analyzer of block 50, to distinguish “suspicious” and “abnormal” cells from “normal cells” and to exclude “normal” cells from further processing.
  • the preprocessor may determine whether the estimated probability of cellular atypia of the object is greater than a probability level predetermined at particular thresholds based upon statistical discrimination experiments that maximize the classification accuracy of the machine as compared to expert human diagnosis (i.e., the gold standard).
  • the preprocessor may designate the particular cellular object as "suspicious” or "abnormal.” If not, however, the preprocessor may designate the particular cellular object as "normal.” In this way, the preprocessor enriches the cell population at issue in each sample, focusing the cytotechnologist's subsequent analysis on only those cellular objects that are most likely to be of interest.
  • the preprocessor may designate such unknown matter or regions-of-interest as "suspicious.” Alternatively, however, the preprocessor may present the unrecognizable matter to a human and interact with the human as shown by block 47 in Figure 5.
  • the preprocessor may display the object in question on a color-image monitor for consideration by a cytotechnologist, and, based on a review of the object, the cytotechnologist may input to the preprocessor a suggested designation of the object as either "normal” or "suspicious or abnormal.” The preprocessor may then use the information provided by the cytotechnologist to categorize the object. Path "B” in Figure 5 represents the specimens that the preprocessor categorized as "suspicious” or "abnormal.” As shown at block 56, the enriched population of "suspicious" and "abnormal" cellular objects in these samples are then presented to a cytotechnologist for screening.
  • the cytotechnologist may conduct this screening with the assistance of an automated microscope workstation, such as the TRACCELL ® -guided ACCELL ® workstation.
  • an automated microscope workstation such as the TRACCELL ® -guided ACCELL ® workstation.
  • the preprocessor since the preprocessor has already identified the most suspect cellular objects in the sample, the preprocessor may efficiently guide the cytotechnologist to screen only the "worst-case" objects, thereby expediting the screening process.
  • the cytotechnologist's screening of each sample that the preprocessor categorized as "suspicious or abnormal" is preferably aided by a "preview" stage.
  • the preprocessor or other data management machine compiles and presents to the cytotechnologist a variety of a priori information about the specimen, and the cytotechnologist previews this a prior information before actually screening the specimen.
  • This preview is arranged to channel the cytotechnologist's attention toward significant specimen- related information while allowing the cytotechnologist to focus less on insignificant information or "noise" that does not bear on whether the specimen is normal or abnormal.
  • a object of this preview stage is to minimize the possibility of a false negative diagnosis during the cytotechnologist's subsequent screening, by biasing the cytotechnologist's attention toward diagnostically significant information.
  • An additional object of this preview stage is to enable the cytotechnologist to compile more readily the relevant information about the specimen for review by a diagnosing pathologist in relation to specific areas of the specimen.
  • the preprocessor beneficially provides the cytotechnologist with a variety of useful information for consideration by the cytotechnologist.
  • This information may be provided to the cytotechnologist in any convenient fashion and in any form.
  • a file server may store some or all information pertinent to specimens being screened at a given cytology laboratory or at a remote laboratory and may serve one or more "client" preview workstations at which pertinent data is displayed.
  • these preview display workstations may be incorporated in the same units that are used as the screening stations, such as the ACCELL ® workstations.
  • the preview workstation contemplated by the present invention preferably includes at least one computer or video display, or other mechanism for conveying to an observer pertinent information about a specimen.
  • the workstation is human controlled, providing mechanisms to enable the cytotechnologist to flag information displayed in the preview stage that appears to be particularly pertinent.
  • the cytotechnologist reviews the preview information for instance, he or she may operate a mouse or other selection device at the preview workstation, to flag pieces of information that appear to bear on whether the specimen at issue is normal, suspicious, or abnormal.
  • the cytotechnologist flags pieces of information, or as the preprocessor generates pertinent information about the specimen at issue as will be described below, the information may be automatically appended to the electronic database record associated with the specimen, for convenient review by the pathologist.
  • the workstation preferably includes a bar code reader and mechanism for scanning a bar code or other indicia, to provide a cytotechnologist with the preview data associated with a particular specimen.
  • the bar code reader 221 of the ACCELL ® screening station may serve to initiate a preview of data pertinent to the specimen under analysis by reading a bar code affixed to the specimen slide.
  • the preprocessor may obtain a portion of its preview information from external sources such as external insurance company, hospital, or physician or laboratory databases or direct data entry, and the preprocessor may generate other preview information based on its direct analysis of the specimen at issue. Regardless of its origin, some or all of this information may be displayed for viewing by the cytotechnologist during the preview stage, in order to bias the cytotechnologist's attention toward more diagnostically significant aspects of the specimen. Therefore, all of this information may be referred to as "biasing- information.”
  • the biasing-information provided to the cytotechnologist by the invention may fall into categories such as (i) patient demographics information, (ii) patient history information such as current or previous test results, (iii) the slide at issue (such as specimen adequacy information (e.g., cellularity and staining adequacy)), and (iv) images of the specimen, each of which will be described in more detail below.
  • This information may be selectively displayed in a single window on the preview display or may, alternatively, be displayed in multiple windows for consideration in combination by the cytotechnologist, as depicted, for instance, in Figures 6a and 6b.
  • this information may take any of a variety of formats, including, for instance, narrative descriptions, tables, charts, plots, digitized (electronic) images, and microscope fields-of- view, as well as enhanced images, annotated images, and comparison displays of combinations of various data types.
  • the preprocessor may compile some of the a priori information about the specimen as it searches for and identifies cellular objects of interest in the sample. As described above, for instance, the preprocessor preferably rank orders the cellular objects in the sample according to their probabilities of cellular atypia, and the preprocessor stores images of the identified cellular objects.
  • the preprocessor may also isolate each image of an atypical or suspicious cell or field-of-view apart from any background images, to facilitate preview display of the diagnostically significant images.
  • the preprocessor may, for example, identify the location of a cellular object or field-of-view in a given digital image and, through automated image processing, eliminate the background around the area of interest and enhance the edges of the object or field-of-view image.
  • the preprocessor may then combine these electronically isolated images together into a visual mosaic image, thereby forming an artificial or virtual specimen or composite field-of-view that consists of cellular objects from the sample without background images or "noise.”
  • This synthesized image simulating a liquid-based preparation may be referred to as an "Electronic Monolayer Preparation" (EMP).
  • EMP Electro Monolayer Preparation
  • the preprocessor may shade the background area, in order to usefully retain a visual context of the cellular object or field-of-view while highlighting the area specifically of interest. This process may require one or more
  • the preprocessor may use pertinent a priori information about the spatial distribution of certain types of samples when identifying and ranking the probabilities of atypia of cellular objects in those samples.
  • the sample is a liquid-based preparation such as a ThinPrep slide (e.g., as shown in Figure 9)
  • the geometry of slide will contain areas of high cellularlity (such as the cellular disk), areas of medium cellularity (such as the bleed zone), areas of low cellularity (such as the annular ring), and areas with ultra-low cellularity (such as areas outside the boundary imprint).
  • the preprocessor may be configured to automatically flag certain other pieces of information as likely to be pertinent to the cytotechnologist's analysis.
  • the preprocessor may be configured to identify specimens that may be unsatisfactory for one reason or another, such as due to questionable collection, fixation or staining. Rather than rejecting such specimens outright, the preprocessor may set a flag indicating that collection may have been unsatisfactory.
  • the preprocessor may be configured to specifically identify clusters of cells in the specimen and to flag such areas of the specimen as likely to be pertinent.
  • the preview workstation displays biasing- information for viewing by the cytotechnologist.
  • one category of such information may be images of the specimen.
  • the preprocessor preferably displays at the preview workstation a discrete set of the apparently "most atypical,” “most suspect,” or “most complex” regions (cellular objects or fields-of-view) for consideration by the cytotechnologist. For instance, these may be the stored images of cellular objects that the preprocessor ranked with highest probabilities of atypia.
  • the preprocessor may display a grid or, alternatively, a visual mosaic (EMP) of a predetermined number of the most suspect objects or fields. These images may depict either the individual cells or fields-of-view with background images removed or shaded as discussed above. Additionally, the preprocessor may highlight some of the images in this display (for instance, with color, texture or shading) based on the preprocessor's automated findings, so as to focus the cytotechnologist's attention on particular matters.
  • EMP visual mosaic
  • the preprocessor may display in conjunction with various discrete images, or in relation to the specimen as a whole, a graphical scale, text or other indicia indicating the preprocessor's degree of confidence in its findings that particular aspects of the specimen are likely to be of interest.
  • the cytotechnologist may flag the object, for instance, by clicking a mouse pointer on the discrete image.
  • the cytotechnologist may further choose to move the specimen physically under manual or computer control to visually review the flagged objects or regions-of-interest.
  • the cytotechnologist may also request the preprocessor to specifically characterize a particular cell. Additionally, the cytotechnologist may manually or automatically input into the specimen record notes or associated information keyed to the discrete cell image, for later review by the diagnosing expert.
  • the cytotechnologist may click on or otherwise select any of these images in order to see an actual microscopic field-of-view or a magnified digital image of the specimen area that includes the cell, as illustrated for instance by Figure 6.
  • the preprocessor may communicate with or serve as the specimen-mapping system (such as the TRACCELL ® system) to direct the screening station (such as the ACCELL ® screening station) to display the associated field-of-view.
  • the screening station such as the ACCELL ® screening station
  • this actual microscopic field-of-view or selected regions-of-interest from that field-of-view may be displayed directly on the same monitor that serves as the preview display. In this way, the cytotechnologist may quickly view the actual context of any cell that the cytotechnologist sees as possibly suspect.
  • the preprocessor displays for preview by the cytotechnologist a series of other pertinent biasing-information, obtained by the preprocessor from external data sources and/or based on its own automated analysis.
  • This information may be displayed on the same or a different display than the discrete images of the cells or fields-of-view. In the preferred embodiment, however, this information is displayed on the same display as the discrete specimen images, so that the cytotechnologist can consider the other information in the context of the specimen images.
  • biasing information may relate to the patient from whom the specimen was drawn and may include, for example, epidimiologic risk factors and abnormal prior physical examinations or laboratory test results.
  • the preprocessor may usefully display an indication of the number of packs of cigarettes per year that the patient has smoked. If the patient has smoked more than a designated number of pack-years, for instance, the technician may wish to flag this information, as the information may bear significantly on whether or not the specimen is from a patient at high risk to develop lung cancer.
  • information about abnormal prior test results may include the results of cellular DNA tests previously conducted on patient specimens.
  • patient information may include, for example, other patient medical records, family medical history, and patient demographics. For instance, this information may include specific patient risk factors for particular diseases based on family history data.
  • Another area of biasing-information may relate to the results of other tests that have been conducted on the same specimen being analyzed, for instance, from samples derived from aliquots of the same specimen, possibly included on a discrete area of the same slide.
  • the results of this test may be usefully displayed at the preview workstation for convenient examination by the cytotechnologist.
  • Figure 6b shows an example of a computer display of a discrete set of nuclear images that appear to be of most interest in a given specimen, together with a DNA histogram and scatterplot display for the same specimen.
  • biasing-information may relate to the slide at issue.
  • This information may include information flagged or noted by the preprocessor based on its analysis of the specimen images.
  • the preprocessor may include on the preview display an indication that a given area of the sample contains a cell cluster and is therefore more likely to be of interest.
  • Information related to the slide at issue may also concern how the slide has been handled or mishandled in the cytology screening laboratory or whether the specimen is satisfactory in accordance with standards such as the Bethesda Classification Code for gynecological specimens. In this regard, pertinent information may concern specimen collection, fixation and/or staining.
  • the specimen that was drawn from the patient may contain an inadequate vaginal, cervical or endocervical component.
  • the sample may contain an insufficient number of cells and therefore be viewed as unsatisfactory.
  • the preprocessor may automatically analyze the stored digital images of the sample to determine whether the sample lacks cells that would be expected to be present in complete samples.
  • specimen fixation those of ordinary skill in the art appreciate that a specimen taken for a Pap smear test must typically be dipped into or sprayed with alcohol immediately after being drawn, in order to preserve the specimen. If the specimen is not properly dipped into or sprayed with alcohol, air drying may rupture the nuclear envelope of the cells or alter the chromatin structure and distribution, creating a blurry effect on the Pap smear slide and decreasing the diagnostic value of the sample.
  • the preprocessor system may be arranged to analyze automatically the stored digital images of the sample to identify the presence of air-drying artifacts, which would reflect poor fixation techniques.
  • the preprocessor may employ automated digital image analysis techniques to determine that the sample was overstained or understained in that it was subjected to too much or too little hematoxylin, for example.
  • the system may determine that the sample was understained in that it was not subjected to enough hematoxylin.
  • the preprocessor may display for examination by the cytotechnologist information identifying the adequacy of staining. The operator may flag such information and thus determine that the specimen at issue should not undergo an accelerated screening process.
  • the cytotechnologist may conveniently identify and note poorly prepared samples and may flag the significant information for pathologist review. Additionally, in the event the cytotechnologist determines, based on this information, that the sample at issue is unsatisfactory for further analysis, he or she may either tag the sample to be returned without further analysis or immediately forward the sample to the expert pathologist for diagnosis.
  • the preprocessor preferably provides the cytotechnologist with access to a referential database to help analyze and place the specimen in context (e.g, with use of AccuMed International, Inc.'s RELATIONAL CYTOPATHOLOGY REFERENCE GUIDETM software).
  • the preprocessor may include or may be locally or remotely interconnected to a database containing information about other specimens. This database may associate particular cellular characteristics with certain circumstantial information similar to the information provided to the cytotechnologist for preview.
  • the cytotechnologist may query the relational database for information about other similar cells, or the preprocessor may be arranged to automatically display pertinent information from the database. In doing so, the preprocessor may conveniently form a search filter based on the information currently flagged by the cytotechnologist. The preprocessor may thereby efficiently obtain database information about similar cells with similar background information.
  • the preprocessor and human technician interact and learn from each other, each gaining additional information that may aid in the cytotechnologist's subsequent screening of the specimen and perhaps ultimately in a pathologist's diagnosis.
  • the cytotechnologist benefits from viewing the biasing-information displayed by the preprocessor, because this information enables the cytotechnologist to focus attention on diagnostically significant aspects of the specimen.
  • the cytotechnologist does not need to spend a significant amount of time looking at the slide.
  • the cytotechnologist may instead assume that the specimen is probably one of the 90% to 95% that are normal, and the cytotechnologist may more rapidly screen the entire slide for any cellular abnormalities.
  • the cytotechnologist may properly spend more than an average amount of time screening this case with a greater than average probability of being abnormal.
  • the present invention beneficially channels the cytotechnologist's attention during actual screening on specimens that are most likely to be suspicious or abnormal.
  • the invention enables the cytotechnologist to avoid spending unnecessary excess time screening specimens that are likely to be within normal limits.
  • the preprocessor may learn significant information about the specimen at issue from actions or behavior of the cytotechnologist, and the preprocessor may use this information — in addition to other information that it gleans from the specimen and/or from external data — to prepare for efficient screening by the cytotechnologist.
  • this information may be as simple as the fact that the cytotechnologist requested an exploded view of a specific specimen region or requested referential database information in comparison to a specific specimen region. Knowing that the cytotechnologist took such action regarding the specific specimen region may signal to the preprocessor that the region is of significance to the cytotechnologist. This may cause the computer to flag an area for expert cytopathologist review even if the screening cytotechnologist did not mark this specific region-of-interest.
  • the preprocessor may acquire information about potentially significant areas of the specimen at issue by monitoring the behavioral patterns of the cytotechnologist during the preview process.
  • some of the reactions of the cytotechnologist even if subconscious, may convey information about significant aspects of the specimen at issue.
  • These cytotechnologist reactions may include, for instance, the movement patterns of the cytotechnologist's eyes viewing the preview screen, the amount of time that the cytotechnologist's eyes focussed on particular pieces of biasing-information, and the cytotechnologist's pupil dilation.
  • the region of new focus may be a diagnostically significant area of the specimen.
  • the preprocessor based on the information that the preprocessor gleans from its automated preprocessing as well as during the preview by the cytotechnologist, the preprocessor next generates a routing function to facilitate automated microscopic display at the screening station of the fields-of-view that contain the "suspicious" or "abnormal" cellular objects (those fields-of view or regions being considered to have the probabilities of atypia of the cellular objects that they contain).
  • a routing function, or routing pattern is keyed to the spatial coordinates on the specimen slide that were recorded during prescreening.
  • the preprocessor may base the routing pattern on any of a variety of criteria.
  • Such criteria may include, for example, the descending order of atypia or complexity previously established, the regions that the cytotechnologist flagged as being of interest during preview, and/or the regions that the preprocessor determined to be suspicious such as those regions that contain cellular fragments or that are overstained or understained.
  • the preprocessor may configure the routing pattern for most efficient physical display at the screening station.
  • the preprocessor may configure the routing function to group specimen regions first by level of interest and then by location on the slide.
  • the system could display the most atypical cell images as shown in Figure 7, using an EMP or alternative display approach.
  • the preprocessor may order the top 25 of those regions by location, the next 25 by location, and so forth. In this way, the screening station will require less movement about the slide to enable screening of the portion of regions designated by the preprocessor.
  • the preprocessor can use a priori information about the spatial distribution of the sample to find the most atypical or suspicious cells on the slide, such as those in the fields-of- view illustrated by Figures 11 and 12, and present those areas to the observer, first. Then, the present invention can guide the observer through the remaining fields-of-view with the other (less suspicious) cellular material.
  • This stratified approach enables the screener to review the cellular material on a liquid-based preparation in a sequence such that the most abnormal cells are likely to be encountered earlier in the screening process.
  • the cytotechnologist next conducts actual screening of "suspicious" or "abnormal” cellular objects in the sample.
  • the screening station preferably displays microscopic fields-of-views of containing the "suspicious" or “abnormal” objects, according to the routing function developed by the preprocessor and at a most efficient rate.
  • ultimate control over the manner of display, such as speed and route remains in the hands of the cytotechnologist, for instance through a control panel, keyboard or other input device provided at the screening station.
  • the invention may also extend to display of these regions-of-interest for review on a computer monitor.
  • the routing function may call for the screening station to display microscopically regions of the specimen in descending order of probability that the regions are of interest. Recognizing that probabilities of interest are likely to diverge more between the specimen regions that are more "atypical,” “suspect” or “complex” than those that are ranked lower by the preprocessor, the screening station may be preset to route more quickly through regions with higher probabilities and slower through other regions. The increase in speed as less interesting regions are displayed for screening may be continuous throughout the screening process. Alternatively, the screening station may, for instance, display a first group of specimen regions at one rate and then another group of regions at another rate. Notwithstanding the automated display in accordance with the routing function, however, the cytotechnologist may at any time elect to stop or manually alter the screening process and custom-adjust the screening times and rates at will.
  • the screening station may be set to display for a minimum period of time regions of the specimen that have been determined to have at a predetermined interest level. For instance, the screening station may be set to display for at least 3 seconds each of the top 10 "most atypical,” “most suspect,” or “most complex” regions. The screening station may then display other regions relatively more quickly, again always allowing the cytotechnologist to interrupt the automated screening process and proceed manually.
  • the system can literally modulate the time allotted per each field-of-view based upon its probability of containing abnormal cells, the complexity of the field-of-view, its cellularity, the staining adequacy and many other parameters.
  • the cytotechnologist may also, or alternatively, set the screening station to route through areas of the specimen in a desired order or at a desired rate. For instance, the cytotechnologist may set the screening station to highlight or stop the screening process at each field-of-view that contains one of the "most atypical,” “most suspect,” or “most complex” cells, objects, or fields-of-view that was displayed during the preview stage. In this way, the cytotechnologist may automatically see these specimen regions in context. As another example, the cytotechnologist may conveniently set the screening workstation to stop automatically at every field-of-view containing one or more of the suspicious cells or at each complex or otherwise flagged field-of-view.
  • the cytotechnologist may set the screening station to stop at only those "most suspicious" cells that the cytotechnologist flagged during the preview stage or to stop at only those fields-of-view that meet specified criteria, such as those containing fragments or those that were understained or overstained.
  • the system can be implemented so that individual laboratories or users can set the operating characteristics individually or laboratory-wide for customization.
  • the screening station may alternatively be prearranged to automatically route through one or more of these fields-of-view with or without direct input from the cytotechnologist.
  • the screening station may be preset or configured by input from the cytotechnologist with a maximum total screening time. This is a significant requirement if this system is being used to re-screen all or many of the apparently WNL specimens for quality assurance.
  • the screening station can then display specimen regions at a rate designed to not exceed the preset maximum time.
  • the cytotechnologist is preferably provided with the ability to interrupt such automated screening at any time, or to proceed with automated screening without the maximum time constraint.
  • the present invention further contemplates that information gleaned during the preview stage may be presented to the cytotechnologist during the screening stage, in conjunction with specimen images being screened.
  • the screening station may display pertinent information about a given field-of-view on a monitor as text or graphics next to the actual field-of-view or overlapped over the field of view.
  • the screening station may display or present indicia such as a sliding bar scale, indicating of the preprocessor's degree of confidence in ranking of probability of interest, similar to that described above in the context of the preview stage.
  • the cytotechnologist determines that the specimen is either (i) suspicious or abnormal, as shown at block 58, or (ii) WNL, as shown at block 62. All of such specimens that the cytotechnologist deems to be suspicious or abnormal are then forwarded to an expert pathologist for review and final diagnosis.

Landscapes

  • Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Computer Hardware Design (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Human Computer Interaction (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Image Processing (AREA)
  • Investigating Materials By The Use Of Optical Means Adapted For Particular Applications (AREA)

Abstract

Un système de dépistage et de diagnostic intégré dans un laboratoire de biologie médicale permet d'effectuer le prétraitement et l'inspection de prélèvements cytologiques ou d'autres échantillons. Un processeur reçoit des images numériques de chaque échantillon et, par analyse statistique, estime les probabilités d'atypie pour des objets ou des régions contenues dans l'échantillon. Le processeur qui se fonde au moins en partie sur ces probabilités estime ensuite une probabilité d'atypie pour l'échantillon d'une manière globale. Un échantillon dont la probabilité d'atypie estimée est suffisamment importante est automatiquement classé comme suspect ou anormal et est à son tour examiné par un technicien humain au moyen d'un système de visualisation et d'un poste de travail de microscope assisté par ordinateur. Un échantillon présentant une probabilité d'atypie suffisamment faible ou nulle est automatiquement classé comme se situant apparemment dans les limites normales et est ensuite examiné par un technicien humain qui effectue la vérification de la qualité ou bien il est classé automatiquement comme se situant dans les limites normales. Après la vérification effectuée par le technicien humain, les échantillons que ce dernier estime comme étant suspects ou anormaux sont réinspectés par un expert qui pose le diagnostic final.
PCT/US1998/014719 1997-07-17 1998-07-17 Systeme d'inspection comprenant le pretraitement des echantillons WO1999004244A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP98935713A EP0995103A1 (fr) 1997-07-17 1998-07-17 Systeme d'inspection comprenant le pretraitement des echantillons
CA002297119A CA2297119A1 (fr) 1997-07-17 1998-07-17 Systeme d'inspection comprenant le pretraitement des echantillons
JP2000503407A JP3916395B2 (ja) 1997-07-17 1998-07-17 検体の予備処理機能を備えた検査体系
AU84900/98A AU8490098A (en) 1997-07-17 1998-07-17 Inspection system with specimen preprocessing

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US5294297P 1997-07-17 1997-07-17
US60/052,942 1997-07-17
US08/895,756 1997-07-17
US08/895,756 US6148096A (en) 1995-09-15 1997-07-17 Specimen preview and inspection system
US94818497A 1997-10-09 1997-10-09
US08/948,184 1997-10-09
US09/034,690 US6430309B1 (en) 1995-09-15 1998-03-04 Specimen preview and inspection system
US09/034,690 1998-03-04

Publications (1)

Publication Number Publication Date
WO1999004244A1 true WO1999004244A1 (fr) 1999-01-28

Family

ID=27488241

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/014719 WO1999004244A1 (fr) 1997-07-17 1998-07-17 Systeme d'inspection comprenant le pretraitement des echantillons

Country Status (5)

Country Link
EP (1) EP0995103A1 (fr)
JP (1) JP3916395B2 (fr)
AU (1) AU8490098A (fr)
CA (1) CA2297119A1 (fr)
WO (1) WO1999004244A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001033196A2 (fr) * 1999-10-29 2001-05-10 Veracel Inc. Reexamen commande d'echantillon medical
WO2001088850A2 (fr) * 2000-05-17 2001-11-22 University Of South Florida Systeme, procede et progiciel informatique permettant d'extraire d'images numeriques des resumes quantitatifs d'informations
JP2003513251A (ja) * 1999-10-29 2003-04-08 サイティック コーポレイション 画像生成システム内のサンプル中の対象領域の位置を検証する装置および方法
AT411066B (de) * 2000-10-24 2003-09-25 Steiner Georg E Verfahren und anordnung zur untersuchung von zellen
WO2004082453A2 (fr) * 2003-03-20 2004-09-30 Retinalyze Danmark A/S Determination de lesions dans une image
US6832873B1 (en) 2000-09-06 2004-12-21 Helmut Kadrnoska Installation vehicle
US20130044940A1 (en) * 2011-08-15 2013-02-21 Molecular Devices, Llc System and method for sectioning a microscopy image for parallel processing
WO2016120418A1 (fr) * 2015-01-31 2016-08-04 Ventana Medical Systems, Inc. Contrôle de qualité d'une analyse automatisée de diapositives entières
WO2017098661A1 (fr) * 2015-12-11 2017-06-15 株式会社島津製作所 Système de gestion d'informations d'analyse
US11835509B2 (en) 2018-04-16 2023-12-05 Evident Corporation Specimen analysis apparatus, specimen analysis method, and computer-readable recording medium

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4490225B2 (ja) * 2004-10-01 2010-06-23 シスメックス株式会社 細胞画像表示方法、細胞画像表示システム、細胞画像表示装置、及びコンピュータプログラム
US9347945B2 (en) 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
CA2821426A1 (fr) * 2005-12-22 2007-07-05 Abbott Laboratories Procede et combinaisons de marqueurs permettant de depister une predisposition au cancer du poumon
WO2012174542A2 (fr) 2011-06-17 2012-12-20 Constitution Medical, Inc. Systèmes et procédés d'affichage et de re-visualisation d'échantillon
WO2013175683A1 (fr) * 2012-05-24 2013-11-28 日本電気株式会社 Système d'évaluation des résultats de diagnostics pathologiques, méthode et dispositif d'évaluation associés
CN107369149B (zh) * 2016-05-11 2020-09-08 富士通株式会社 目标物体的检测装置及方法
JP6967232B2 (ja) * 2017-10-06 2021-11-17 株式会社ニコン 画像処理装置、画像処理方法及び画像処理プログラム
WO2019111365A1 (fr) * 2017-12-06 2019-06-13 オリンパス株式会社 Dispositif d'évaluation d'échantillon, méthode d'évaluation d'échantillon et programme

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513438A (en) * 1982-04-15 1985-04-23 Coulter Electronics, Inc. Automated microscopy system and method for locating and re-locating objects in an image
US4812909A (en) * 1986-08-12 1989-03-14 Hitachi, Ltd. Cell classification apparatus capable of displaying a scene obtained by superimposing a character scene and graphic scene on a CRT
WO1995002204A1 (fr) * 1993-07-09 1995-01-19 Compucyte Corporation Codeur informatise d'echantillons examines au microscope
EP0647844A2 (fr) * 1993-10-12 1995-04-12 F. Hoffmann-La Roche Ag Dispositif et méthode de cytologie interactive automatisée
WO1996003709A1 (fr) * 1994-07-26 1996-02-08 Neuromedical Systems, Inc. Dispositif et procede de controle
US5625705A (en) * 1994-06-03 1997-04-29 Neuromedical Systems, Inc. Intensity texture based classification system and method
WO1997025678A1 (fr) * 1996-01-11 1997-07-17 Neopath, Inc. Visualisation et analyse sur reseau de microplaquettes codees par ordinateur

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513438A (en) * 1982-04-15 1985-04-23 Coulter Electronics, Inc. Automated microscopy system and method for locating and re-locating objects in an image
US4812909A (en) * 1986-08-12 1989-03-14 Hitachi, Ltd. Cell classification apparatus capable of displaying a scene obtained by superimposing a character scene and graphic scene on a CRT
WO1995002204A1 (fr) * 1993-07-09 1995-01-19 Compucyte Corporation Codeur informatise d'echantillons examines au microscope
EP0647844A2 (fr) * 1993-10-12 1995-04-12 F. Hoffmann-La Roche Ag Dispositif et méthode de cytologie interactive automatisée
US5625705A (en) * 1994-06-03 1997-04-29 Neuromedical Systems, Inc. Intensity texture based classification system and method
WO1996003709A1 (fr) * 1994-07-26 1996-02-08 Neuromedical Systems, Inc. Dispositif et procede de controle
WO1997025678A1 (fr) * 1996-01-11 1997-07-17 Neopath, Inc. Visualisation et analyse sur reseau de microplaquettes codees par ordinateur

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001033196A2 (fr) * 1999-10-29 2001-05-10 Veracel Inc. Reexamen commande d'echantillon medical
WO2001033196A3 (fr) * 1999-10-29 2002-04-04 Veracel Inc Reexamen commande d'echantillon medical
JP2003513251A (ja) * 1999-10-29 2003-04-08 サイティック コーポレイション 画像生成システム内のサンプル中の対象領域の位置を検証する装置および方法
JP4771636B2 (ja) * 1999-10-29 2011-09-14 サイティック コーポレイション 画像生成システム内のサンプル中の対象領域の位置を検証する装置および方法
WO2001088850A2 (fr) * 2000-05-17 2001-11-22 University Of South Florida Systeme, procede et progiciel informatique permettant d'extraire d'images numeriques des resumes quantitatifs d'informations
WO2001088850A3 (fr) * 2000-05-17 2002-04-25 Emmanuel Lazaridis Systeme, procede et progiciel informatique permettant d'extraire d'images numeriques des resumes quantitatifs d'informations
US6832873B1 (en) 2000-09-06 2004-12-21 Helmut Kadrnoska Installation vehicle
AT411066B (de) * 2000-10-24 2003-09-25 Steiner Georg E Verfahren und anordnung zur untersuchung von zellen
WO2004082453A3 (fr) * 2003-03-20 2005-08-11 Retinalyze Danmark As Determination de lesions dans une image
WO2004082453A2 (fr) * 2003-03-20 2004-09-30 Retinalyze Danmark A/S Determination de lesions dans une image
US20130044940A1 (en) * 2011-08-15 2013-02-21 Molecular Devices, Llc System and method for sectioning a microscopy image for parallel processing
US8731278B2 (en) * 2011-08-15 2014-05-20 Molecular Devices, Inc. System and method for sectioning a microscopy image for parallel processing
WO2016120418A1 (fr) * 2015-01-31 2016-08-04 Ventana Medical Systems, Inc. Contrôle de qualité d'une analyse automatisée de diapositives entières
US10573001B2 (en) 2015-01-31 2020-02-25 Ventana Medical Systems, Inc. Quality control of automated whole-slide analyses
WO2017098661A1 (fr) * 2015-12-11 2017-06-15 株式会社島津製作所 Système de gestion d'informations d'analyse
JPWO2017098661A1 (ja) * 2015-12-11 2018-07-19 株式会社島津製作所 分析情報管理システム
US11835509B2 (en) 2018-04-16 2023-12-05 Evident Corporation Specimen analysis apparatus, specimen analysis method, and computer-readable recording medium

Also Published As

Publication number Publication date
JP2003521669A (ja) 2003-07-15
CA2297119A1 (fr) 1999-01-28
AU8490098A (en) 1999-02-10
EP0995103A1 (fr) 2000-04-26
JP3916395B2 (ja) 2007-05-16

Similar Documents

Publication Publication Date Title
US6430309B1 (en) Specimen preview and inspection system
US6148096A (en) Specimen preview and inspection system
JP2831282B2 (ja) 対象物評価の相互連関方法
US5939278A (en) Automated histological specimen classification system and method
JP3916395B2 (ja) 検体の予備処理機能を備えた検査体系
US6535626B1 (en) Inspection system with specimen preview
JP5469070B2 (ja) 生物検体を処理するための複数の波長を用いる方法およびシステム
EP0745243B9 (fr) Procedes de classification automatique de prelevements cytologiques
Brenner et al. Automated classification of normal and abnormal leukocytes
US5889880A (en) Interactive automated cytology method incorporating both manual and automatic determinations
US20150262355A1 (en) Method and system for processing an image of a biological specimen
US20220335736A1 (en) Systems and methods for automatically classifying cell types in medical images
EP0995102B1 (fr) Systeme d'inspection comprenant une previsualisation des echantillons
US20230360414A1 (en) Systems and methods for processing images to determine image-based computational biomarkers from liquid specimens
CA2185511C (fr) Systeme d'analyse d'un specimen cytologique avec les donnees individuelles pour chaque patient
Coleman Evaluation of automated systems for the primary screening of cervical smears
US7906337B2 (en) Method of generating and using biological qualification slides to qualify biological screening devices
Eden et al. Feasibility of computer screening of blood films for the detection of malaria parasites
CA2182793C (fr) Systeme et procede de classification automatique de prelevements cytologiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2297119

Country of ref document: CA

Ref country code: CA

Ref document number: 2297119

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998935713

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998935713

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998935713

Country of ref document: EP